KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Expenses: 2011-2025

Historic Operating Expenses for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $252.3 million.

  • Supernus Pharmaceuticals' Operating Expenses rose 87.13% to $252.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $718.5 million, marking a year-over-year increase of 21.22%. This contributed to the annual value of $580.2 million for FY2024, which is 5.33% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Operating Expenses stood at $252.3 million, which was up 64.59% from $153.3 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Operating Expenses registered a high of $252.3 million during Q3 2025, and its lowest value of $107.2 million during Q2 2021.
  • For the 3-year period, Supernus Pharmaceuticals' Operating Expenses averaged around $159.9 million, with its median value being $152.8 million (2024).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Operating Expenses decreased by 18.52% in 2023, and later soared by 87.13% in 2025.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Operating Expenses stood at $153.0 million in 2021, then decreased by 13.05% to $133.0 million in 2022, then grew by 24.30% to $165.3 million in 2023, then fell by 7.60% to $152.8 million in 2024, then surged by 87.13% to $252.3 million in 2025.
  • Its Operating Expenses was $252.3 million in Q3 2025, compared to $153.3 million in Q2 2025 and $160.1 million in Q1 2025.